Previous studies on proteomics and early pathobiological events demonstrated that urinary angiotensinogen (AGT) and urinary matrix metalloproteinase-7 (MMP-7) could be used as AKI biomarkers for clinical applications (Chen C et al., 2016; Yang et al., 2017). This evidence concerns the gene AGT and acute kidney injury.